Stereotactic ablative radiation therapy (SABR)

RADIATION3 trials

Sponsors

Indiana University, University of Maryland, Baltimore

Conditions

Lung CancerOligometastatic DiseaseProstate Cancer

Phase 2

SABR for T1-2a N1 NSCLC

WithdrawnNCT03321760

Indiana UniversityLung Cancer

Start: 2022-01-01End: 2027-12-31Updated: 2022-02-09

TERPS Trial for de Novo Oligometastic Prostate Cancer

RecruitingNCT05223803

University of Maryland, BaltimoreOligometastatic Disease, Prostate Cancer

Start: 2022-10-18End: 2029-07-31Target: 122Updated: 2026-06-03

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Active, not recruitingNCT06212583

University of Maryland, BaltimoreOligometastatic Disease, Prostate Cancer

Start: 2024-04-17End: 2029-12-31Target: 88Updated: 2026-05-06

Related Papers

Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.

Journal of Clinical Oncology2025-02-101 citations

Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial.

Journal of Clinical Oncology2023-02-201 citations